Diagnosing HIV and AIDS is a systematic process that combines clinical evaluation, laboratory testing, and long-term follow-up. Doctors confirm whether a patient is infected with the human immunodeficiency virus (HIV) through detailed medical history inquiries, symptom analysis, and multi-stage biological testing, and assess the stage of the disease. Early diagnosis not only allows for the initiation of antiviral treatment but also effectively blocks virus transmission; therefore, the medical community emphasizes the importance of proactive screening and regular follow-up.
The diagnostic process typically consists of three stages: initial screening, confirmatory testing, and disease staging assessment. Screening may be conducted through blood, saliva, or home testing kits, while confirmatory testing requires laboratory techniques such as Western blot or nucleic acid amplification tests. The diagnosis of AIDS also requires the combination of CD4+ T cell counts, viral load, and the presence of specific complications to determine the extent of immune system damage. The following details each diagnostic step and key techniques.
Clinical evaluation is the foundation of diagnosis. The doctor will first inquire about the patient's exposure risks and symptom history. Early HIV infection may present with flu-like symptoms such as fever, swollen lymph nodes, or rash, but these non-specific manifestations cannot confirm a diagnosis on their own. Therefore, the assessment must explore the following key information in detail:
During the clinical evaluation, the doctor will also assess the patient's general health status, including skin examination, lymph node palpation, and organ function assessment. For example, symptoms of oral candidiasis or Pneumocystis pneumonia may suggest the possibility of late-stage AIDS.
Screening tests are divided into antibody/antigen combination tests (such as fourth-generation ELISA) and nucleic acid amplification tests (NAT). Antibody/antigen tests can detect the viral protein p24 and antibodies, suitable for patients 2-6 weeks post-infection. NAT directly measures viral RNA, which, while highly sensitive, is more costly and often used as a primary screening tool for high-risk populations.
Saliva testing and home self-testing kits (such as rapid antibody tests) provide non-invasive options, but it is important to note that self-test results must be confirmed by a professional medical unit. For example, some self-testing tools may yield false-negative results due to operational errors or early infection, necessitating confirmation with blood tests.
When screening results are positive, confirmatory testing must be conducted to rule out false positives. Common methods include Western blot immunoblotting or immunofluorescence assays (IFA), which can differentiate the reaction patterns of antibodies and specific viral proteins. For instance, Western blot can show specific bands for gp41 or gp120 antigens, confirming the presence of infection.
Viral genotyping analysis is used for resistance assessment, especially in cases of treatment failure, by interpreting mutations in the viral strain through gene sequencing, assisting in adjusting drug combinations. Such tests are typically performed at the beginning of treatment and during monitoring.
Proactive screening is a key aspect of diagnosis. The Centers for Disease Control and Prevention (CDC) recommends that all adults aged 13-64 be screened at least once, with high-risk groups needing annual checks. Currently, commonly used screening tools include:
Assessment tools also include the "clinical staging system," which categorizes AIDS into Stage 1 to Stage 3 based on CD4+ T cell counts and specific complications. For example, Stage 3 indicates severe immune deficiency, with common indicators including CD4+ cell counts below 200 cells/μL or the presence of AIDS-defining illnesses.
The symptoms of HIV infection can easily be confused with other immune-related diseases, necessitating differential diagnosis to rule out other possibilities:
In the AIDS stage, differentiation from malignancies (such as lymphoma), tuberculosis, or Pneumocystis pneumonia is required. For instance, when a patient presents with persistent dry cough and difficulty breathing, chest X-rays and pathological biopsies are needed to distinguish between pulmonary infections or malignancies.
Early diagnosis can significantly improve prognosis. Antiretroviral therapy (ART) can reduce viral load to undetectable levels, allowing the patient’s immune system to recover. According to data from the World Health Organization (WHO), early treatment can reduce the risk of transmission by 95% and delay disease progression to the AIDS stage.
For individuals, early diagnosis provides both psychological and physiological support. Patients can receive counseling, nutritional support, and complication prevention early on. For example, starting treatment within three months of infection allows CD4+ T cell recovery to occur 2-3 times faster than late treatment. On a societal level, early diagnosis can break the chain of virus transmission, reducing the rate of infection in the population.
However, some patients delay seeking medical attention due to fear or social stigma, leading to a diagnosis at the AIDS stage. Therefore, medical institutions often combine anonymous screening with mental health support to enhance the willingness of high-risk groups to undergo testing. For instance, some countries provide free home testing kits linked to hotline counseling services.
Home or temporary screening station rapid antibody tests have a sensitivity of about 99% and a specificity of over 99.5%. However, it is important to note that positive results must be confirmed with laboratory tests (such as Western blot or nucleic acid tests) for verification. It is recommended to test three months after the incubation period to ensure accuracy.
After starting antiretroviral therapy (ART), is it still necessary to regularly monitor CD4 cell counts and viral load?Yes, even if the viral load is undetectable after treatment, it is still recommended to monitor CD4 cell counts and viral load every 3-6 months to assess the recovery of the immune system and whether the virus has developed resistance. If CD4 counts fall below 200/μL or viral load rises, adjustments to the drug regimen may be necessary.
If a teenager under 18 is diagnosed with HIV, can they use adult dosages of medication directly?It is not recommended to use adult dosages directly; teenagers need to adjust medication dosages based on weight and developmental stage, and choose drugs with less impact on liver and kidney function. Medical guidelines suggest that those over 12 years old may use standard adult treatment regimens, but regular assessments of growth and development by an infectious disease physician are necessary.
If the 72-hour golden window for post-exposure prophylaxis (PEP) is missed, will the efficacy significantly decrease?If more than 24 hours have passed without taking the medication, the missed dose should be taken immediately. However, if it is close to the next scheduled dose, the missed dose should be skipped, and doubling up on medication is not allowed. Delayed medication may lower the success rate of prevention; therefore, it is recommended to set reminders every 4 hours to strictly adhere to the medication schedule.
Will casual contact (such as sharing meals or shaking hands) transmit the virus from someone undergoing effective treatment?No. Modern medicine has confirmed that when HIV-infected individuals adhere to their medication regimen and maintain a viral load below 200 copies/mL, they are non-infectious (U=U principle). The viral concentration in saliva, sweat, and urine is extremely low, and casual contact such as sharing utensils, kissing, or touching wounds does not result in infection.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
